COVID-19 “Long-Haulers” Receiving Potentially Addictive Prescriptions

We’ve written about the collision of the COVID-19 and opioid epidemics. Now, there is a new intersection between the two.   Long-Haulers Receiving Prescriptions at Higher Rates More than three million people who have had COVID-19 are considered “long-haulers,”[1] meaning their symptoms linger for weeks or months after first becoming infected. In order to treat these…

OUD Healthcare

Study Evaluates Healthcare Quality for People With Opioid Use Disorder

A study published April 8th measured the quality of care that people with opioid use disorder (OUD) receive for healthcare unrelated to OUD.[1] It analyzed preventative care, chronic illness treatment, and care coordination in 79,372 insured people with OUD—and for comparison, 46,601 insured people without OUD. The study used data from OptumLabs Data Warehouse, which…

OUD Study

Study Finds Physician-Pharmacist Collaboration Effective in Treating Opioid Use Disorder

A study[1] published last month, supported by the National Institute on Drug Abuse (NIDA), found an effective way to treat opioid use disorder (OUD). The approach prioritizes collaboration between physicians and pharmacists in administering and monitoring Buprenorphine, a medication used to treat OUD. Doctors and Pharmacists Worked Together Participants did an initial screening with a…

Vivitrol

Can Vivitrol Be Addictive?

Vivitrol is the brand name and injectable form of Naltrexone. Naltrexone is an opioid antagonist, meaning it blocks the effects of opioids. It also binds to the endorphin receptors in the body, blocking the sedative and euphoric feelings people get from substances like alcohol and opioids.   Because of these effects, Vivitrol is used to treat…